SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending due to significant momentum and volume, leading to a breakout and potential short squeeze. Community members are actively discussing profit-taking strategies, with some suggesting the stock could become the next low-float runner. The stock's low float and potential for a squeeze are major talking points.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amidst heated debate and strong opinions regarding a recent shooting involving conservative figure Charlie Kirk. The community is actively discussing political motivations, affiliations of the suspect, and the broader implications for political discourse. This heightened attention coincides with existing volatility around the stock itself.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

The crypto $WAGMI.X is trending amid community excitement and the circulation of a new community song, fueling discussions around its potential as a leading culture coin. Many community members are rolling profits into $WAGMI.X, drawn to its active community and the sentiment that it's poised for a breakout within the meme coin cycle on the $SOL.X blockchain. Bullish sentiment is high, with many viewing it as a long-term play.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to the excitement surrounding its upcoming listing on BiFinance and a live 'Biggest Buy Contest', which the community sees as key catalysts. The community emphasizes that the project is built on organic growth and hard work, not hype, and they are rallying together to push the coin to new all-time highs. Many community members express strong conviction and encourage others to DYOR and join their Telegram group to learn more.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

ATYR is trending as traders anticipate Phase 3 data, expected mid-September, with the community actively debating potential outcomes and price targets. Bullish sentiment is fueled by recent institutional buying and analyst ratings, while bears cite concerns over trial design and past performance, with some highlighting the involvement of controversial figures known for short selling. The potential for a short squeeze and the high implied volatility are adding to the speculative buzz.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recently announced $20 million investment agreement, sparking significant price movement and active discussion about its potential. The community is focused on the stock's low float and speculating about a potential short squeeze, while also keeping an eye on an upcoming investor summit. Some traders are also wary of dilution and high volatility.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP.X is trending as the community speculates on potential catalysts, including a possible spot ETF and upcoming rate cuts, while also closely monitoring price action and key resistance levels. Discussions include both bullish sentiment, with some anticipating a significant breakout, and skepticism regarding its performance compared to other cryptocurrencies. Traders are actively debating strategies around accumulating and holding versus taking profits.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities is trending as the community anticipates a potential short squeeze following the completion of its merger with Strive Enterprises; traders are closely watching for a CUSIP change and its potential impact on short positions. Chatter revolves around the possibility of the company investing its substantial treasury into Bitcoin, drawing comparisons to other companies in the crypto space. Some traders express frustration that the price has not yet reflected the merger news and the potential for a short squeeze.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station ($GEMI) is trending after its IPO, with the community actively discussing its potential and comparing it to other recent IPOs. Some investors are excited about the company's prospects and credit card rewards program, while others express concerns about its valuation and potential for a pullback. The stock's initial trading volatility and comparison to other crypto-related companies are also key talking points.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

$TROLL.X is gaining attention following news of officially acquiring rights to the Trollface meme, sparking a surge in market cap and community excitement. Technical analysis suggests a bullish uptrend with potential for a breakout, as buyers actively stack and momentum builds. The community also draws comparisons to other meme coins like $SHIB.X and discusses potential for high returns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of -28.05% and -0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of UroGen Pharma gained momentum after the U.S. FDA approved Zusduri, a therapy for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer, prompting a flurry of bullish analyst revisions and heightened interest from retail investors.UroGen Pharma shares jumped 8.6% to $12.03 on Friday, hitting a three-month high, and edged up further to $12.06 in after-hours trading.Goldman SachsGoldman Sachs raised its price target to $16 from $3, noting the stock’s 22% post-approval rally surprised most investors, given the negative ODAC vote and briefing document that had flagged an unfavorable benefit-risk profile.&nbsp;In a note, analyst Paul Choi reminded investors that FDA approvals following negative oncology advisory panels are “exceedingly rare.”&nbsp;The firm remains ‘Neutral’ on the stock despite the unexpected regulatory success.OppenheimerOppenheimer raised its target to $31 from $10, reiterating an ‘Outperform’ rating and emphasizing a key update from Friday’s conference call—a $21,500 per-dose list price for Zusduri.&nbsp;Analyst Leland Gershell expects clarity on UGN-103's path to approval will help preserve franchise exclusivity beyond 2031, adding that sales could reach $1 billion over time.&nbsp;He also said he would “take advantage of any near-term weakness to buy UroGen shares.”ScotiabankScotiabank lifted its target to $47 from $23, increasing its FDA approval probability from 60% to 100%.&nbsp;The firm continues to rate the stock ‘Outperform,’ citing a $1 billion peak market opportunity for Zusduri and revising valuation models accordingly.<a href="https://stocktwits.com/news-articles/markets/equity/urogen-price-target-upgrade-after-fda-approval-for-cancer-medicine/chli4GKRRbJ">Guggenheim and D. Boral</a> also reaffirmed bullish views on UroGen Pharma, calling the FDA's early approval of Zusduri a 'surprise decision' that bypassed further trial requirements and validated regulatory flexibility in high-unmet-need cancer settings.The drug, a combination of mitomycin and sterile hydrogel, is administered once weekly for six weeks via catheter, offering a non-surgical alternative to transurethral resection of bladder tumors, the current standard of care.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.The stock has risen 12.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

UroGen Pharma Stock Scores Bullish Price Target Revisions Up To $47 Following FDA Nod For Zusduri

UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer.

Equity

Shares of UroGen Pharma (URGN) shot up 9% on Friday morning after Guggenheim hiked its price target on the stock on the heels of the U.S. Food and Drug Administration approving its Zusduri medication.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.urogen.com/news-releases/news-release-details/us-fda-approves-urogens-zusduritm-mitomycin-intravesical">approved</a> Zusduri for adults with a type of cancer of the lining of the bladder called recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) on Thursday. Zusduri consists of mitomycin and sterile hydrogel and is designed for potent tumor ablation.Patients can receive their Zusduri dose from a healthcare provider once a week for 6 weeks into the bladder through a urinary catheter, as opposed to the existing standard of care which is a surgical procedure called transurethral resection of bladder tumor.Guggenheim subsequently raised the firm's price target on UroGen Pharma to $30 from $15 while keeping a ‘Buy’ rating on the shares.The new price target implies a near 171% upside to the stock’s closing price of $11.08 on Thursday.The FDA approval for Zusduri, a day ahead of the deadline, is "a surprise decision" following the negative Oncologic Drug Advisory Committee (ODAC) vote during an FDA advisory committee meeting last month, the analyst told investors, as per TheFly.Last month, the ODAC committee narrowly voted against its benefit/risk profile, effectively ending hopes for approval as the FDA considers independent advice from the committee.The firm believes this outcome represents a best-case scenario for UroGen, given that the marketing approval indicates a broad indication of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, without the need to conduct another large randomized controlled trial and "only minor safety warnings."D. Boral Capital analyst Jason Kolbert, meanwhile, reiterated a ‘Buy’ rating and $25 price target on UroGen Pharma. The approval validates the FDA's willingness to exercise flexibility in high-unmet-need indications, despite divided advisory input, the analyst said.Zusduri is expected to be available in the U.S. on or around July 1, 2025, for the treatment of adults with recurrent LG-IR-NMIBC. LG-IR-NMIBC affects approximately 82,000 people in the U.S. each year, and of those, an estimated 59,000 are recurrent cases.On Stocktwits, retail sentiment around UroGen rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume increased from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1274/136;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_9_30_23_AM_png_01d194b268.webp" alt="URGN's Sentiment Meter and Message Volume as of 9:30 a.m. ET on Jun 13, 2025 | Source: Stocktwits" width="1274" height="136"><figcaption>URGN's Sentiment Meter and Message Volume as of 9:30 a.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism that the stock would reach $20.<stembedurl>https://stocktwits.com/TarriffKing007/message/617822498</stembedurl><a href="https://stocktwits.com/symbol/URGN">URGN stock</a> is up approximately 13% this year but down by 31% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-inks-5.3-billion-deal-with-cspc-pharma-for-new-drug-candidates/chli5sARRbG">AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20

The new price target of $30 implies a near 171% upside to the stock’s closing price of $11.08 on Thursday.

Shares of biotech company UroGen Pharma Ltd. (URGN) plummeted 48% on Wednesday noon after the company said that a committee of the U.S. Food and Drug Administration (FDA) voted in opposition to a favorable benefit-risk profile for its investigational drug UGN-102, an intravesical solution for the treatment of a recurrent form of bladder cancer.CEO Liz Barrett <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250521737507/en/UroGen-Announces-Outcome-of-Oncologic-Drugs-Advisory-Committee-for-UGN-102-for-the-Treatment-of-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-Bladder-Cancer-LG-IR-NMIBC">said</a> the company is "disappointed" by the outcome of the meeting of FDA’s Oncologic Drugs Advisory Committee (ODAC), but added that the company believes in the clinical data in support of the drug.Low-grade intermediate-risk nonmuscle-invasive bladder cancer has no FDA-approved therapies, the CEO said, while adding that it is looking forward to working with the FDA as they complete their review of its new drug application (NDA).The FDA considers independent advice from ODAC, which weighs down the possibility of approval. The FDA is expected to conclude its review of the application by June 13.UGN-102 for intravesical solution is an innovative drug formulation of mitomycin, an antibiotic used as a drug in cancer treatment. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.The company said the adverse impacts identified with the treatment in its late-stage trial, such as urine retention, are typically manageable in routine urologic practice. &nbsp;UroGen submitted its NDA to the FDA in August 2024. If approved in June, the company initially said it would make the product available in July.On Stocktwits, retail sentiment around UroGen remained unchanged within the ‘extremely bullish’ territory over the past 24 hours while message volume stayed put at ‘extremely high’ levels. &nbsp;<figure class="image"><img style="aspect-ratio:626/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_21_at_1_58_13_PM_png_0f90b9f92d.webp" alt="URGN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 21, 2025 | Source: Stocktwits" width="626" height="65"><figcaption>URGN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 21, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/URGN">URGN stock</a> is down by about 64% this year and nearly 71% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/shopify-bets-on-gen-ai-with-new-ai-tools-to-simplify-store-creation-but-stock-drops/ch0eOwYRbYo">Shopify Bets On Gen-AI With New AI Tools To Simplify Store Creation But Stock Drops</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

UroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s Unruffled

The Food and Drug Administration is expected to conclude its review of UroGen’s UGN-102 application by June 13.

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will...

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced expansion of its...

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from the...

UroGen Pharma to Present at Upcoming Investor Conferences

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month...

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of...

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

URGN
UroGen Pharma Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest URGN News

URGN UroGen Pharma Ltd